Dawn Carter Bir Reata Pharmaceuticals Inc (RETA) insider trading activity

Dawn Carter Bir is Chief Commercial Officer of REATA PHARMACEUTICALS INC. Currently has a direct ownership of 0 shares of RETA, which is worth approximately $0. The most recent transaction as insider was on Sep 26, 2023, when has been sold 33,805 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Dawn Carter Bir Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 26 2023	SELL Sale (or disposition) back to the issuer	-	33,805 Reduced 100.0%	0 Class A Common Stock
Aug 16 2023	SELL Open market or private sale	$66,995 $168.33 p/Share	398 Reduced 1.16%	33,805 Class A Common Stock
Aug 15 2023	SELL Open market or private sale	$136,415 $169.04 p/Share	807 Reduced 2.31%	34,203 Class A Common Stock
Jul 28 2023	SELL Open market or private sale	$6,581,600 $164.54 p/Share	40,000 Reduced 53.33%	35,010 Class A Common Stock
Jul 28 2023	BUY Conversion of derivative security	-	40,000 Added 34.78%	75,010 Class A Common Stock
Jul 06 2023	BUY Grant, award, or other acquisition	-	4,125 Added 10.54%	35,010 Class A Common Stock
May 16 2023	SELL Open market or private sale	$33,756 $80.95 p/Share	417 Reduced 1.33%	30,885 Class A Common Stock
May 15 2023	SELL Open market or private sale	$76,070 $85.09 p/Share	894 Reduced 2.78%	31,302 Class A Common Stock
Mar 13 2023	SELL Open market or private sale	$808,436 $86.77 p/Share	9,317 Reduced 22.44%	32,196 Class A Common Stock
Mar 07 2023	SELL Open market or private sale	$3,610,566 $85.88 p/Share	42,042 Reduced 50.32%	41,513 Class A Common Stock
Mar 07 2023	BUY Conversion of derivative security	-	41,630 Added 33.25%	83,555 Class A Common Stock
Mar 06 2023	SELL Open market or private sale	$4,933,770 $89.78 p/Share	54,954 Reduced 56.72%	41,925 Class A Common Stock
Mar 06 2023	BUY Conversion of derivative security	-	48,370 Added 33.3%	96,879 Class A Common Stock
Mar 03 2023	SELL Open market or private sale	$191,149 $88.25 p/Share	2,166 Reduced 4.27%	48,509 Class A Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	15,675 Added 23.62%	50,675 Class A Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	35,000 Added 50.0%	35,000 Class A Common Stock
Nov 09 2020	SELL Open market or private sale	$9,750,000 $162.5 p/Share	60,000 Reduced 100.0%	0 Class A Common Stock
Nov 09 2020	BUY Conversion of derivative security	-	60,000 Added 50.0%	60,000 Class A Common Stock

Also insider at

GERN

GERON CORP Healthcare

SLNO

SOLENO THERAPEUTICS INC Healthcare

DCB

Dawn Carter Bir

Chief Commercial Officer

Plano, TX

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RETA shares.

Notify only if

Value

Insider Trading

Get notified when an Reata Pharmaceuticals Inc insider buys or sells RETA shares.

Notify only if

Operation

Value

Type

News

Receive news related to REATA PHARMACEUTICALS INC

Track Activities on RETA

Account